|
IKT Inhibikase Therapeutics Inc 1750149 |
| Income Statement |
|
Net Income
|
2026-06-30
|
$-19,591,231.00 |
| Balance Sheet |
|
Current Assets
|
$162,343,915.00 |
|
Assets
|
$163,588,612.00 |
|
Current Liabilities
|
$10,260,026.00 |
|
Liabilities
|
$10,260,026.00 |
|
Equity
|
$153,328,586.00 |
|
Shares Out
|
132032636.00 |
| Cash Flow Statement |
|
Operating Cash Flow
|
$-24,503,334.00 |
|
Investing Cash Flow
|
$-86,393,289.00 |
| Market Analysis |
Market Cap
|
$310,276,694.60 |
|
Price
|
$2.35 |
|
BVPS
|
1.16 |
|
PB
|
2.03 |
|
EPS
|
-0.11 |
|
FCF
|
$-24,503,334.00 |
|
| Dividends |
|
Dividend Data Last Updated
|
2026-09-01 09:32:46 |
|
|
| Earnings |
|
Earnings Last Updated
|
2026-09-14 10:01:37 |
|
| Apr |
May |
Jun |
| 2026-03-26 |
-0.49 |
|
|
2026-05-12 |
-0.10 |
|
| Jul |
Aug |
Sep |
|
|
|
|
2025-08-14 |
-0.11 |
|
| Oct |
Nov |
Dec |
|
|
|
|
2025-11-14 |
-0.13 |
|
|
Find a discrepancy? The most accurate way to find company fundamental data is to view IKT documents filed with the SEC.
IKT Filings
Clear
